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ABSTRACT 
Alzheimer’s disease as well as prion-related encephalopathies are 
neurodegenerative disorders of the central nervous system, which cause 
mental deterioration and progressive dementia. Both pathologies appear to be 
primarily associated with the pathological accumulation and deposit of -
amyloid or prion peptides in the brain, and it has been even suggested that 
neurotoxicity induced by these peptides would be associated to essentially 
similar pathogenic mechanisms, in particular to those that follow the activation 
of microglial cells. To probe whether the neurotoxic effects induced by the -
amyloid and prion peptides are actually mediated by similar glial-associated 
mechanisms, we have examined the differential expression of genes in SH-
SY5Y neuroblastoma cells incubated with conditioned media from -amyloid or 
prion-stimulated THP-1 monocytic cells. According to microarray analysis, not 
many coincidences are observed and only four genes (Hint3, Psph, Daam1 and 
c-Jun) appear to be commonly upregulated by both peptides. Furthermore, c-
Jun appears to be involved in the cell death mediated by both peptides. 
 
INTRODUCTION 
Alzheimer and prion pathologies are neurodegenerative diseases 
characterized by the progressive loss of neuronal synaptic function, an effect 
that in both cases appears to be secondary to the toxicity induced by key 
proteins, the beta-amyloid (A) in Alzheimer’s disease and PrP in prion 
pathologies, which accumulate and aggregate in the brain. At first sight, both 
types of pathologies exhibit different specific characteristics in relation with the 
mode of transmission, the etiology, or the frequency of occurrence, and they 
can be considered as essentially distinct pathologies (Checler & Vincent, 2002). 
However, despite these evident differences, these pathologies also show a 
number of similarities. In both cases neurodegeneration appears to be 
mediated by proteins that, as mentioned above, are aggregated and 
accumulated in the brain (Price et al., 1993). Those proteins share a complex 
multi-domain structure and contain toxic sequences that mediate neurotoxicity 
and give rise to similar damaging apoptotic phenotypes (Checler & Vincent, 
2002). Moreover, they share a number of properties such as the presence of 
metal-binding sites that mediate the binding of metals ions, in particular copper 
or zinc (Barnham et al., 2006), or the existence of several repeats of a GxxxG 
motif in the transmembrane region, which contain a methionine residue that 
appears to be essential to modulate the neurotoxicity of A in Alzheimer or the 
disease susceptibility in the prion associated pathologies (Barnham et al., 
2006). Evidence reported in those articles supported the hypothesis that 
neurotoxicity induced by both proteins, the amyloid and prion, would be 
mediated by similar, if not identical, molecular pathways and opened a very 
attractive possibility as is the use of common therapeutic strategies to treat and 
prevent Alzheimer’s and prion diseases.  
Unfortunately, this hypothesis appears to be too simplistic, and although it 
is evident that both the -amyloid and the PrP proteins are neurotoxic and 
induce similar processes of apoptosis and neurodegeneration, the factors and 
pathways that mediate these effects could be essentially different (Forloni et al., 
1996; Hope et al., 1996; Brown et al., 1997). In this sense, we have also 
reported that both the amyloid-beta 25-35 (A25-35) and the PrP106-126 
fragments induce a distinct gene expression profile in the human SH-SY5Y 
neuroblastoma cell line. First, the number of genes significantly altered by 
these treatments was markedly different, 198 in the case of the prion (Martinez 
& Pascual, 2007b), and 67 in the case of the amyloid fragment (Martinez & 
Pascual, 2007a), and second, the relationship between the overexpressed and 
repressed genes was opposite in both cases (16/182 and 54/13, respectively).  
Despite this, it has been also well established that in addition to those 
effects directly induced on neurons, neurotoxicity of both peptides can be 
largely mediated by microglia activation, and the consequent release of 
cytotoxic molecules such as proinflammatory cytokines or reactive oxygen 
intermediates. In fact, an increasing body of evidence indicates that neuronal 
death induced by the -amyloid and the prion peptides in the brain is mainly 
associated to processes that are promoted by activation of the surrounding 
microglial cells (Dheen et al., 2007). To analyze possible coincidences between 
the neurotoxic effects induced by both peptides through activation of microglia, 
we have now analyzed the gene expression profile in SH-SY5Y neuroblastoma 
cells exposed to conditioned media obtained from A25-35 or PrP106-126 
stimulated THP-1 human monocytic cells, which were used as a surrogate 
model of human microglia.  
 
MATERIALS AND METHODS 
Cell Culture and treatments 
Human monocytic THP-1 cells and SH-SY5Y human neuroblastoma cells 
were cultured as previously described (Combs et al., 1999; Villa et al., 2002) in 
RPMI 1640 medium supplemented with 10% fetal bovine serum (Gibco.Life 
technologies Ltd. Paislay. Scotland. UK), and maintained at 37ºC in a 5% CO2 
atmosphere.  
Synthetic A25-35 obtained from AnaSpec and synthetic PrP106-126 
obtained from Neosystem, were prepared as follows: Briefly, A25-35 was 
dissolved in deionized-distilled water at a concentration of 2,5 mM and stored at 
−80 °C. Previous to the experiments, the stock solution was diluted to the 
desired concentrations and then added to the culture medium. The prion 
peptide 106-126 was dissolved in PBS at a concentration of 2 mM and 
maintained for 48 hours at room temperature to allow polymerization, before 
being added to the cells. 
For experiments, THP-1 monocytes were incubated for 48 hours with or 
without 10 M A25-35 or 10M PrP106-126, and the conditioned media 
collected and centrifuged to eliminate cell residues. The cell-free supernatants 
were then used to replace the culture media of SH-SY5Y cells previously plated 
in 6-well plates and grown for 24 hours in RPMI/10%FBS media. Six hours after 
addition of conditioned media a set of cells was harvested for posterior RNA 
extraction and determination of gene expression. The remaining cells were 
incubated in the presence or in the absence of conditioned media for 24 hours 
and then photographed and fixed for histological analysis or collected and 
saved for subsequent protein or RNA extraction. 
Fluorescence microscopy  
SH-SY5Y cells were incubated for different time periods with the 
supernatants of amyloid- or prion-treated THP-1 cells or RPMI fresh medium, 
and then fixed with 4% paraformaldehyde at pH=7,4 and room temperature for 
1 hour, permeabilized with 0,1% Triton-X-100, and then subjected to TUNEL 
assay to evaluate the cellular death by using the in situ cell death detection kit 
Fluorescein (Roche). To further confirm the findings of TUNEL assay, cells 
were washed with PBS, stained with DAPI, and analyzed by fluorescence 
microscopy, using a Zeiss Axiophot inverted fluorescence microscope (515-565 
nm for TUNEL, and 450-480 nm for DAPI). Images of cells were then digitized 
using an Olympus DP70 color camera. 
MTT cell viability assay 
Cell viability was evaluated in 96-well culture plates using a colorimetric 
assay based on the reduction of tetrazolium dye (MTT) to a blue formazan 
product. After incubation for 4 h with MTT (0.5 mg/ml) at 37°C, isopropanol/HCl 
was added to each 96-well and the absorbance of solubilized MTT formazan 
products was measured spectrophotometrically at 570 nm.  
RNA interference 
Expression of c-Jun in the SH-SY5Y cells was inhibited by using the 
Santa Cruz Biotechnology c-Jun siRNA (h2) (catalog number sc-44201). Cells 
were grown to 60% confluence and the c-Jun siRNA or a control siRNA (catalog 
number sc-37007) were transfected (using the transfection reagent sc-29528) 
according to the manufacturer’s instructions. At 24 h after transfection, the 
medium was replaced and the cells were further incubated for 48 h. Next, media 
were removed and the cells were exposed to the THP-1 conditioned 
supernatants for 24 h. 
RNA preparation and Microarray Analysis 
For RNA isolation cell lysates were homogenized and the RNA purified by 
using the QIAshredder and RNeasy Mini kits of Qiagen, according to the 
manufacturer's recommendations. The final amount of isolated RNA was 
determined in each sample by spectrophotometry and its quality assessed by 
electrophoresis on agarose gels.  
Preparation of cDNA, cRNA, hybridization and scanning of microarrays 
were performed following manufacturer’s protocols. cDNA, and biotinylated 
cRNAs were synthesized from 5g RNA samples with the GeneChip 
expression 3’ amplification reagents (one-cycle cDNA synthesis, and IVT 
labelling) kits of Affymetrix, and biotinylated probes were hybridized to an 
Affymetrix gene chip human genome U133A Plus 2.0 array, a microarray that 
contains more than 54,000 probe sets and allows an accurate analysis of the 
quantitative expression of over 47,000 transcripts, including 38,500 well 
characterized human genes. Analysis for differential expression was performed 
using the R platform for statistical analysis (R Foundation for Statistical 
Computing. Vienna) and several packages from the Bioconductor project 
(Gentleman et al., 2004; Carey et al., 2005). The raw data were imported into R 
and pre-processed using the affy package and the robust multichip average 
method (Irizarry et al., 2003). Genes were selected based on fold change. For 
this task an absolute fold change of 1.6 was used.  
RT-PCR amplification of mRNA 
RT-PCR was used to validate the differential expression of several A- or 
PrP-responsive genes detected in the microarray analysis. Total RNA was 
extracted from cell cultures as mentioned above and cDNA was prepared from 
250 ng of RNA using the high-capacity cDNA reverse transcription kit (Applied 
Biosystems, Foster City, CA). For quantitative PCR, a cDNA aliquot 
corresponding to 5 ng of the starting RNA was used, with Taqman Assay-on-
Demand primers and the Taqman universal PCR master mix, No Amp Erase 
UNG (Applied Biosystems) on a 7900HT fast real-time PCR system (Applied 
Biosystems). The PCR program consisted in a hot start of 95 C for 10 min, 
followed by 40 cycles of 15 sec at 95 C and 1 min at 60 C. PCRs were 
performed in triplicates, using the 18S gene as internal standard and the 2-
cycle threshold method for analysis (Livak & Schmittgen, 2001). 
Statistical analysis. 
When appropriate, the significance of differences was calculated with the 
Student's t test, and it was indicated in the corresponding figure by the following 
symbol: * p < 0,05 and ** p< 0.01. 
 
RESULTS 
Effects of the THP-1 conditioned medium on neuronal morphology and 
viability. 
It is widely accepted that both the -amyloid and prion peptides induce 
microglial activation and the subsequent secretion of cytokines and neurotoxic 
reactive oxygen species (Forloni et al., 1993; Klegeris et al., 1997), which in 
turn may increase neuronal apoptosis (Dheen et al., 2007).  
To further analyze and compare how the -amyloid- and prion-stimulated 
microglia may affect neurons, we have exposed SH-SY5Y neuroblastoma cells 
to conditioned media obtained from THP-1 cells, a monocytic cell line that 
exhibits responses to stimuli similar to those of microglia (Combs et al., 1999). 
THP-1 cells were incubated with or without 1,2 5 or 10M A25-35 or PrP106-
126 for a 48 h time period and the recovered conditioned media was added to 
SH-SY5Y neuroblastoma cells that were then incubated for an additional 24 
hours time period. The morphology and viability of cells were estimated by 
optical microscopy, TUNEL and DAPI staining (figure 1), and by MTT assay 
and Western blot analysis of caspase-3 (figure 2).  
As illustrated in figure 1, morphology and viability of cells were not 
affected by conditioned medium from THP-1 cells treated with scrambled 
sequences, with 5M A25-35 or PrP106-126 (panel A), or with lower doses of 
those peptides. However, the cell morphology as well as the viability appeared 
to be severely affected after 24 hours of exposition to conditioned media from 
10M A25-35 or PrP106-126 treated THP-1 cells (panel B). As shown in this 
panel, a large amount of neuroblastoma cells become apoptotic after 24 hours 
incubation with conditioned media from 10 M A25-35 or PrP106-126 treated 
cells. The number of cells was clearly reduced by both treatments and the 
residual cells became more rounded in appearance. Figure 2 includes the 
results obtained in a representative MTT assay (panel A), which confirms the 
reduced viability of cells, and the levels of activated caspase-3 detected by 
Western blot (panel B), which corroborated that apoptosis was significantly 
increased in SH-SY5Y cells incubated with those supernatants obtained from 
amyloid- or prion-stimulated THP-1 cells. All together, these results evidence 
that cell death was drastically increased in SH-SY5Y cells exposed for 24 hours 
to conditioned media recovered from amyloid- or prion-stimulated THP-1 cells. 
Gene expression profile in SH-SY5Y cells incubated in THP-1 cells-
conditioned culture media. 
To analyze how the amyloid- and prion-activated microglia may affect the 
gene expression profiling in neurons, SH-SY5Y cells were exposed to 
conditioned media for a 6 hours time period and then harvested and saved for 
posterior RNA extraction and microarray analysis. Gene expression was 
analyzed by using an Affymetrix U133A plus2 array and the data analyzed as 
described under Materials and Methods.  
As expected, both the amyloid- and prion-conditioned media induced 
changes on the gene expression profile of treated SH-SY5Y cells. A 
significance analysis of microarrays highlighted a relatively high number of 
transcripts differentially expressed in cells exposed to conditioned media from 
the THP-1 monocytic cells stimulated by the amyloid or prion fragments. 
However, the intensity of the response was rather low and not many genes 
change their expression by more than 1.6-fold. Of interest, the gene expression 
profiles appear to be different in both cases. First, the number of genes that 
change their expression appears to be much higher in amyloid-treated cells 
than in those cells exposed to the prion-conditioned medium. Second, whereas 
the genes affected by the prion-induced media appear to be mainly 
upregulated, the genes differentially expressed in cells exposed to the amyloid-
conditioned media were largely down-regulated. These results are illustrated in 
the Venn diagram shown in figure 3, which outlines the total number of 
sequences up- and down-regulated, as well as the number of coincidences, 
detected in cells exposed to both treatments. As illustrated in this figure, a total 
of 168 sequences, 19 upregulated and 149 down-regulated, in cells exposed to 
the amyloid peptide-conditioned media, and a total of 17 sequences, all of them 
upregulated, in the cells treated with the prion-conditioned media, were found to 
be differentially expressed (above 1,6 fold with respect to control). After 
subtracting non annotated sequences and repeated probes the number of 
amyloid- and prion-induced genes were reduced to 141 (129 down- and 12 
upregulated) and 11 (all of them upregulated), respectively. Furthermore, four 
of these sequences appeared to be commonly upregulated by both treatments.   
The lists of the differentially expressed transcripts has been included in 
tables 1 (amyloid) and 2 (prion), which, as mentioned before, only include 
transcripts showing a 1,6-fold variation above or below the level found in the 
control.  
Validation of the microarray data 
 To confirm the results obtained in the microarray analysis, the 
expression of a subset of genes selected from those identified in the microarray 
was analyzed by real-time PCR performed with cDNAs prepared from the 
RNAs of SH-SY5Y cells treated, or untreated, with conditioned media 
recovered from prion- or amyloid-stimulated THP-1 cells.  
 Transcripts chosen for confirmation included a total of 9 genes selected 
among those commonly deregulated by both the prion- and amyloid-
conditioned media and/or because of their involvement in development and 
plasticity of the nervous system. As expected, the results from real-time PCR 
analysis were comparable to those provided by microarray analysis and, 
although in some of the samples the intensity of the response was different to 
that expected, all the transcripts analyzed showed the predicted differential 
expression patterns.  Figure 4 shows the results obtained for five of these 
genes, two of them (JUN and DAAM1) commonly regulated by both treatments, 
and other three genes (STMN4, CREB5, and ETNK1) selected because of their 
contribution to the Jun-dependent signaling pathways. In agreement with the 
microarray data, four of these genes appear to be upregulated by both 
treatments, whereas ETNK1 that is down regulated in the amyloid treated cells 
remains unchanged in cells treated with the prion-stimulated medium. In 
addition, the differences obtained with the other analyzed genes (HINT3, 
CREB1, BCLAF1 and MAP3K) were not significant, but also showed the same 
tendency observed in the microarrays (not shown).  
c-Jun silencing decreases the monocytic-mediated cell death 
  To further prove the role of c-Jun in the apoptotic signals induced 
by the amyloid and prion peptides, we also analyzed the levels of activated 
caspase-3 and the cell viability in SH-SY5Y cells transfected with a specific c-
Jun small interference RNA (c-Jun siRNA), which reduced c-Jun levels by 
about 50-60% (Figure 5). As shown in the panel A of this figure, the levels of 
cleaved caspase-3 were, as expected, increased in control cells transfected 
with a non-specific siRNA and exposed to supernatants recovered from the 
prion- or amyloid-stimulated THP-1cells. However, a significant decrease in 
caspase-3 cleavage was observed in SH-SY5Y cells transfected with the 
specific c-Jun siRNA, thus suggesting a role for this protein in the apoptotic 
pathways induced by both peptides. In addition, cell viability (MTT assay) was 
not significantly affected by c-Jun depletion in the absence of the peptide 
fragments, but the reduction of cell viability induced by the A- or PrP-
stimulated conditioned media was stronger in the c-Jun expressing cells than in 
the in the siRNA-transfected cells (panel B), further supporting a role for c-Jun 
in those processes.  
 
DISCUSSION 
Neurodegenerative diseases, in particular Alzheimer´s disease and prion 
associated pathologies have been shown to share a number of characteristics 
and it has been even suggested that neurotoxicity induced by both, the amyloid 
and prion proteins, would be mediated by similar, if not identical, molecular 
pathways and mechanisms. In this sense, several factors have been already 
pointed as common targets of A and prions (Ferreiro et al., 2006; Ferreiro et 
al., 2007; Lopes et al., 2007), and common therapies based on these 
descriptions have been suggested (Checler & Vincent, 2002; Barnham et al., 
2006). In contrast, a number of discordances have been also described. As 
shown in a number of in vitro studies, A and PrP peptides appear to induce 
neuronal apoptosis through different mechanisms (Forloni et al., 1996; Hope et 
al., 1996) (Brown et al., 1997). Also in this line, we have described different 
gene expression profiles in neuroblastoma cells directly exposed to A25-35 
and PrP106-126 synthetic fragments (Martinez & Pascual, 2007b; a). However, 
in these reports we just described the effects directly induced by the prion and 
amyloid proteins on neurons, whereas neurotoxicity of both peptides has been 
proved to be further enhanced by the presence of glial (mostly microglial) cells 
(Dheen et al., 2007). In fact, the number of glial cells has been described to 
correlate with the amyloid or prion deposition (Van Everbroeck et al., 2004), 
and it has been suggested that activation of microglia by A or PrP and the 
subsequent release of cytokines, reactive oxygen species and other neurotoxic 
factors would be the main cause of the enhanced apoptosis and neuronal death 
observed both in Alzheimer and prion diseases. To analyze possible 
coincidences in the microglia-mediated neuronal response to those peptides we 
have exposed neuroblastoma SH-SY5Y cells to conditioned media obtained 
from A- or PrP-stimulated THP-1 monocytic cells, a established cell line widely 
used as a model for human microglia because of their functional similarities 
with primary microglia and their ability to activate similar signalling pathways 
(McDonald et al., 1997; Combs et al., 1999). As expected, exposure of 
neuroblastoma cells to conditioned media from A or PrP-treated THP-1 cells 
caused a significant increase of cell death that was clearly detectable by optical 
microscopy, and further proved by TUNEL staining and caspase-3 activation. In 
addition, we have also identified a number of genes whose expression appears 
to be deregulated in cells exposed to conditioned media. In both cases, it is 
noteworthy that amyloid-associated effects were always more evident that 
those induced by the prion-stimulated medium. First, the A25-35 conditioned 
media appeared to be more toxic than that conditioned by PrP106-126 and 
apparently caused a higher lethality, as observed by optical microscopy. 
Second, in contrast to that observed when these peptides act directly on 
neurons (Martinez & Pascual, 2007b; a), the number of genes deregulated by 
A25-35 was markedly higher than the number of genes affected by the prion-
conditioned media. Indeed, whereas A25-35-induced medium changes the 
expression of 141 genes by more than 1,6-fold with respect to the control 
group, only 11 genes were altered by the PrP106-126 fragment.  
On the other hand, a comparative analysis of these results with those 
previously described in neuroblastoma cells directly exposed to the amyloid or 
prion fragments, shows a number of additional differences between the direct 
and macrophage-mediated effects induced by both peptides. So, whereas the 
amyloid fragment appears to activate similar pathways and processes both 
acting directly on neurons or indirectly through monocytic activation, the effects 
of the PrP106-126 peptide are largely different when exerted directly or 
indirectly on neurons.  
Despite these marked differences, it is remarkable the common activation 
of four genes in cells exposed to both treatments; Hint3, which has not been 
previously associated to neurodegenerative pathologies; Psph that is widely 
expressed in neuronal ganglia and Daam1 and c-Jun, which as previously 
described play a role in the developing and injured nervous system (Kida et al., 
2004; Zhou et al., 2004). In particular, it results of interest the macrophage-
mediated upregulation of c-JUN, a gene that has been associated to axon 
regeneration (Raivich et al., 2004; Zhou et al., 2004), to brain inflammation and 
to a wide number of processes involved in neuronal cell death and 
degeneration (Raivich, 2008). Moreover, a direct relationship between the 
JNK/c-Jun cascade and the Alzheimer’s disease (Sun et al., 2009) or prion-
related pathologies (Lee et al., 2005) has been suggested. In the present study 
the role of c-Jun in the apoptotic processes induced by the A25-35 and 
PrP106-126 peptides has been confirmed by the reduced levels of cleaved 
caspase-3, an apoptotic marker, and the partial reversal of the cell viability 
reduction found in SH-SY5Y cells depleted of c-Jun by means of a specific 
siRNA. 
In conclusion, our data show a number of divergences between the genes 
and mechanisms that mediate the neurotoxicity of A and PrP peptides but, 
remarkably, also show the common activation of a reduced number of genes 
including c-Jun, which codes for a transcription factor largely involved in 
apoptotic processes. In this sense, PCR analysis also shows the upregulation of 
Creb5 a member of the CRE (cAMP response element)-binding protein family, 
which as previously reported (Dong et al., 2007) may specifically interact with c-
Jun and function as a CRE-dependent transactivator. These results further 
confirm previous descriptions about the role of c-Jun in neurodegenerative 
processes and reinforce the JNK/c-Jun pathway as a valuable target for the 
development of common therapeutic strategies. However, it is also true that our 
experiments have been carried out using two established cell lines as models, 
and it could occur that they do not accurately reflect the microglial-mediated 
neuronal toxicity that both the amyloid and prion peptides exert in vivo. In any 
case, these results might contribute to increase the knowledge about the 
mechanisms that mediate the neurotoxicity of both the amyloid and the prion 
peptides and should be useful to develop new and specific multitargeted 
therapies for these diseases. 
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LEGEND TO THE FIGURES  
Figure 1. Neurotoxic effects of the conditioned medium from cells treated with 
the 25–35 -amyloid and 106–126 PrP fragments. SH-SY5Y cells were cultured 
for 24 h in the absence (control) or in the presence of conditioned media from 
-amyloid- or prion-treated THP-1 monocytic cells, and the cell death was 
assessed by optical microscopy, DAPI staining and TUNEL analysis. Panel A 
illustrates results obtained with conditioned media from THP-1 cells treated with 
5M A25–35 or PrP106–126 (left), or with 10M of the corresponding 
scrambled peptides (right). Panel B shows the effects of conditioned media 
from THP-1 cells exposed to 10M A25–35 or PrP106–126. 
 
Figure 2. Viability of SH-SY5Y cells incubated with or without THP-1 
conditioned media. Cell death was evaluated by MTT assay or Western blot 
detection of activated caspase-3. Panel A illustrates the results obtained in a 
representative MTT assay performed in quadruplicate. Data (mean ± S.D) are 
expressed relative to the values obtained in control cells **P < 0.01. Panel B 
shows the Western blot determination of cleaved caspase-3 and -tubulin 
(loading control).  
 
Figure 3. Venn diagram showing transcripts distribution between the amyloid 
and prion treated cells. The diagram was generated from lists of transcripts that 
are ≥1.6-fold up- (↑) or down- (↓) regulated by both treatments. 
 
Figure 4. Validation of microarray data by quantitative reverse transcriptase 
polymerase chain reaction (RT-PCR). The differential expression of some 
genes identified in the microarray assay was analyzed by quantitative RT-PCR 
carried out with RNA obtained from cells treated for 6 h with or without A25-35- 
or PrP106–126-conditioned media. Data are expressed as fold change relative 
to control values obtained in untreated cells. *P < 0.05, **P < 0.01. 
 
Figure 5. Silencing of c-Jun protects cells against A and PrP toxicity. SH-SY5Y 
cells, transfected with a control (left) or a c-Jun specific siRNA (right), were 
incubated for 24 hours with conditioned media from -amyloid or prion-
stimulated THP-1 cells. Panel A illustrates the Western blot determination of c-
Jun, cleaved caspase-3 and -tubulin (loading control). Panel B illustrates the 
results obtained in a MTT assay performed in quadruplicate. Data (mean ± S.D) 
are expressed relative to the values obtained in cells transfected with the 
control siRNA in the absence of peptide fragments. **P < 0.01 
 
Table 1. Deregulated genes in SH-SY5Y cells incubated for 6 hours with media 
conditioned by A25-35-treated THP-1 cells. Table includes up and 
downregulated genes that change their expression by more than 1.6-fold with 
respect to the control group (Nonannotated or repeated genes have been 
excluded of this table).  
 
Table 2. Deregulated genes in SH-SY5Y cells incubated for 6 hours with media 
conditioned by PrP106-126-treated THP-1 cells. Table includes upregulated 
genes that change their expression by more than 1.6-fold with respect to the 
control group. Not genes were found decreasing their expression by more than 
1,6-fold. List does not included non annotated or repeated genes. 
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Table 1. Deregulated genes in Aβ25-35-treated cells
                                Downregulated genes 
Gene symbol Gene name Fold change
BCLAF1 BCL2-associated transcription factor 1 -2.35
TWF1 twinfilin, actin-binding protein, homolog 1 (Drosophila) -2.31
GNA13 guanine nucleotide binding protein (G protein), alpha 13 -2.3
SCD stearoyl-CoA desaturase (delta-9-desaturase) -2.27
MALAT1 metastasis associated lung adenocarcinoma transcript 1 -2.2
SKP2 S-phase kinase-associated protein 2 (p45) -2.19
ANKRD10 ankyrin repeat domain 10 -2.17
CDK6 cyclin-dependent kinase 6 -2.17
CEP170L centrosomal protein 170kDa-like -2.13
TAF9B TAF9B RNA polymerase II, TATA box binding protein (TBP)-associated -2.13
XIST X (inactive)-specific transcript (non-protein coding) -2.1
DCUN1D1 DCN1, defective in cullin neddylation 1, domain containing 1 -2.08
PTPN12 protein tyrosine phosphatase, non-receptor type 12 -2.08
COPA coatomer protein complex, subunit alpha -2.07
SUPT16H suppressor of Ty 16 homolog (S. cerevisiae) -2.07
PIK3C2A phosphoinositide-3-kinase, class 2, alpha polypeptide -2.06
PPAT phosphoribosyl pyrophosphate amidotransferase -2.06
SMC3 structural maintenance of chromosomes 3 -2.06
SCD stearoyl-CoA desaturase (delta-9-desaturase) -2.04
EXOC5 exocyst complex component 5 -2.02
SLC39A6 solute carrier family 39 (zinc transporter), member 6 -2
NUCKS1 nuclear casein kinase and cyclin-dependent kinase substrate 1 -1.99
GULP1 GULP, engulfment adaptor PTB domain containing 1 -1.97
PHTF2 putative homeodomain transcription factor 2 -1.97
CBX5 chromobox homolog 5 (HP1 alpha homolog, Drosophila) -1.95
CLIC4 chloride intracellular channel 4 -1.95
CDC27 cell division cycle 27 homolog (S. cerevisiae) -1.89
LOC100190986 hypothetical LOC100190986 -1.89
MEX3C mex-3 homolog C (C. elegans) -1.89
TMX1 thioredoxin-related transmembrane protein 1 -1.89
YTHDF3 YTH domain family, member 3 -1.88
EIF4A2 eukaryotic translation initiation factor 4A, isoform 2 -1.87
TMEM30A transmembrane protein 30A -1.87
BRCC3 BRCA1/BRCA2-containing complex, subunit 3 -1.85
EXOC4 exocyst complex component 4 -1.85
GTF2I general transcription factor II, i -1.85
JAM3 junctional adhesion molecule 3 -1.85
PNRC2 proline-rich nuclear receptor coactivator 2 -1.85
SCAMP1 secretory carrier membrane protein 1 -1.85
ZNF24 zinc finger protein 24 -1.85
C5orf22 chromosome 5 open reading frame 22 -1.84
CREB1 cAMP responsive element binding protein 1 -1.84
LARP4 La ribonucleoprotein domain family, member 4 -1.84
USP10 ubiquitin specific peptidase 10 -1.84
DHX9 DEAH (Asp-Glu-Ala-His) box polypeptide 9 -1.83
MCL1 myeloid cell leukemia sequence 1 (BCL2-related) -1.83
NUDT21 nudix (nucleoside diphosphate linked moiety X)-type motif 21 -1.83
CD46 CD46 molecule, complement regulatory protein -1.82
ACTR2 ARP2 actin-related protein 2 homolog (yeast) -1.8
SLC16A1 solute carrier family 16, member 1 (monocarboxylic acid transporter 1) -1.8
Table1
SRPK1 SFRS protein kinase 1 -1.8
VPS35 vacuolar protein sorting 35 homolog (S. cerevisiae) -1.8
BCAT1 branched chain aminotransferase 1, cytosolic -1.8
C10orf18 chromosome 10 open reading frame 18 -1.79
FYTTD1 forty-two-three domain containing 1 -1.79
WAC WW domain containing adaptor with coiled-coil -1.79
CPD carboxypeptidase D -1.78
IGF2BP3 insulin-like growth factor 2 mRNA binding protein 3 -1.78
MTPAP mitochondrial poly(A) polymerase -1.78
G3BP2 GTPase activating protein (SH3 domain) binding protein 2 -1.77
TOB1 transducer of ERBB2, 1 -1.77
UBXN4 UBX domain protein 4 -1.77
DDX3X DEAD (Asp-Glu-Ala-Asp) box polypeptide 3, X-linked -1.75
FAM29A family with sequence similarity 29, member A -1.75
JAK1 Janus kinase 1 (a protein tyrosine kinase) -1.75
NFYA nuclear transcription factor Y, alpha -1.75
ANP32E acidic (leucine-rich) nuclear phosphoprotein 32 family, member E -1.74
EML4 echinoderm microtubule associated protein like 4 -1.74
IPO8 importin 8 -1.74
MAP3K1 mitogen-activated protein kinase kinase kinase 1 -1.74
CDV3 CDV3 homolog (mouse) -1.73
DEPDC1 DEP domain containing 1 -1.73
PTAR1 protein prenyltransferase alpha subunit repeat containing 1 -1.73
RPRD1A regulation of nuclear pre-mRNA domain containing 1A -1.73
ZDHHC17 zinc finger, DHHC-type containing 17 -1.73
CCDC88A coiled-coil domain containing 88A -1.73
ATP13A3 ATPase type 13A3 -1.72
CBFB core-binding factor, beta subunit -1.72
GABRB3 gamma-aminobutyric acid (GABA) A receptor, beta 3 -1.72
MATR3 matrin 3 -1.72
PBRM1 polybromo 1 -1.72
PIP5K1A phosphatidylinositol-4-phosphate 5-kinase, type I, alpha -1.72
PREPL prolyl endopeptidase-like -1.72
RC3H2 ring finger and CCCH-type zinc finger domains 2 -1.72
RDX radixin -1.72
TEX15 testis expressed 15 -1.72
CANX calnexin -1.69
CCDC88A coiled-coil domain containing 88A -1.69
FAF1 Fas (TNFRSF6) associated factor 1 -1.69
SCAMP1 secretory carrier membrane protein 1 -1.69
APOOL apolipoprotein O-like -1.68
ELOVL2 elongation of very long chain fatty acids (FEN1/Elo2, SUR4/Elo3)-like 2 -1.68
GDAP1 ganglioside-induced differentiation-associated protein 1 -1.68
GLS glutaminase -1.68
HECTD1 HECT domain containing 1 -1.68
RAB35 RAB35, member RAS oncogene family -1.68
DUSP6 dual specificity phosphatase 6 -1.67
HIPK1 homeodomain interacting protein kinase 1 -1.67
KIF5B kinesin family member 5B -1.67
MTMR1 myotubularin related protein 1 -1.67
SRPR signal recognition particle receptor (docking protein) -1.67
TIA1 TIA1 cytotoxic granule-associated RNA binding protein -1.67
TMPO thymopoietin -1.67
ZNF146 zinc finger protein 146 -1.67
CASC5 cancer susceptibility candidate 5 -1.66
CNTN1 contactin 1 -1.66
CRKL v-crk sarcoma virus CT10 oncogene homolog (avian)-like -1.66
FNDC3A fibronectin type III domain containing 3A -1.66
MAT2A methionine adenosyltransferase II, alpha -1.66
UTRN utrophin -1.66
CDC2L5 cell division cycle 2-like 5 (cholinesterase-related cell division controller) -1.65
CTDSPL2 CTD (carboxy-terminal domain, RNA polymerase II, polypeptide A) small -1.65
ETNK1 ethanolamine kinase 1 -1.65
HNRNPU heterogeneous nuclear ribonucleoprotein U (scaffold attachment factor A -1.65
MBTPS2 membrane-bound transcription factor peptidase, site 2 -1.65
NARG2 NMDA receptor regulated 2 -1.65
RBM14 RNA binding motif protein 14 -1.65
TMEM194A transmembrane protein 194A -1.65
Sep-11 septin 11 -1.64
CACNA2D1 calcium channel, voltage-dependent, alpha 2/delta subunit 1 -1.64
G2E3 G2/M-phase specific E3 ubiquitin ligase -1.64
NAMPT nicotinamide phosphoribosyltransferase -1.64
SNX13 sorting nexin 13 -1.64
ADAM10 ADAM metallopeptidase domain 10 -1.6
BAG4 BCL2-associated athanogene 4 -1.6
HSPH1 heat shock 105kDa/110kDa protein 1 -1.6
KCTD20 potassium channel tetramerisation domain containing 20 -1.6
MBNL1 muscleblind-like (Drosophila) -1.6
RORB RAR-related orphan receptor B -1.6
                          Upregulated genes
STMN4 stathmin-like 4 2.3
CREB5 cAMP responsive element binding protein 5 2.28
HINT3 histidine triad nucleotide binding protein 3 1.92
JUN jun oncogene 1.87
IDH2 isocitrate dehydrogenase 2 (NADP+), mitochondrial 1.83
DAAM1 dishevelled associated activator of morphogenesis 1 1.78
PSPH phosphoserine phosphatase 1.73
AMOTL2 angiomotin like 2 1.72
METT10D methyltransferase 10 domain containing 1.67
RAP2C RAP2C, member of RAS oncogene family 1.67
C4orf30 chromosome 4 open reading frame 30 1.66
DUSP10 dual specificity phosphatase 10 1.64
                               Upregulated genes
Gene symbol Gene name
Fold 
change
HINT3 histidine triad nucleotide binding protein 3 1.91
SMA4 glucuronidase, beta pseudogene 1.89
SLITRK6 SLIT and NTRK-like family, member 6 1.77
DAAM1 dishevelled associated activator of morphogenesis 1 1.73
JUN jun oncogene 1.68
C21orf45 chromosome 21 open reading frame 45 1.66
PSPH phosphoserine phosphatase 1.65
GRIA2 glutamate receptor, ionotropic, AMPA 2 1.64
C15orf40 chromosome 15 open reading frame 40 1.64
LYZ lysozyme (renal amyloidosis) 1.64
Table 2. Deregulated genes in PrP106–126-treated cells
Table 2
In this paper we have analyzed the monocyte-mediated gene expression profile 
induced by the amyloid an prion peptides in the human SH-SY5Y 
neuroblastoma cell line.  Results show a relevant coincidence in activating the 
expression of four genes Hint3, Psph, Daam1 and c-Jun. Furthermore, c-Jun 
appears to be involved in the cell death mediated by both peptides. 
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Answers to reviewer 2 
 
As requested, we have now included those results not illustrated or mentioned 
as not shown in the former manuscript. They are shown in the new figures 1 
and 5, and a short description has been added into the text and legends.  
 
- As indicated in our previous version “the effect was not induced by scrambled 
sequences and was not observed with doses of A25-35 or PrP106-126 lower 
5M (data not shown)”. These results have been now included in figure 1A, 
although because their extension in the new figure we have just included the 
results corresponding to the higher dose of those compound, that is 5M. Of 
course, if you consider it is necessary, we could also include the results 
obtained with the other doses tested (1 and 2 M), that of course were also 
unable to reduce cell viability.  
 
- In addition, the results obtained in the MTT assay have been included in figure 
5. Now it is possible to observe how the reduction of cell viability induced by 
both fragments is partially reversed in cells transfected with the c-Jun siRNA, 
thus suggesting a role for Jun in those processes. 
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